Research ArticleAccepted Article
When has a knee or hip replacement failed? A patient perspective
Jasvinder A. Singh, Bella Mehta, Serene Z. Mirza, Mark P. Figgie, Peter Sculco, Michael Parks and Susan M. Goodman
The Journal of Rheumatology December 2019, jrheum.191024; DOI: https://doi.org/10.3899/jrheum.191024
Jasvinder A. Singh
Birmingham Veterans Affairs (VA) Medical Center, Birmingham, AL; Department of Medicine at the School of Medicine, and Division of Epidemiology at the School of Public Health, University of Alabama at Birmingham, Birmingham, AL 35233; Department of Medicine and Department of Orthopedic Surgery, Hospital for Special Surgery, 535 E 70th Street New York, NY 10021. Grant Support: JAS is supported by the resources and the use of facilities at the VA Medical Center at Birmingham, Alabama, USA. No grant funding was obtained for this study. Financial Conflict: There are no financial conflicts related directly to this study. JAS has received consultant fees from Crealta/Horizon, Medisys, Fidia, UBM LLC, Medscape, WebMD, the National Institutes of Health and the American College of Rheumatology. JAS owns stock options in Amarin pharmaceuticals and Viking therapeutics. JAS is a member of the executive of OMERACT, an organization that develops outcome measures in rheumatology and receives arms-length funding from 36 companies. JAS is a member of the Veterans Affairs Rheumatology Field Advisory Committee. JAS is the editor and the Director of the UAB Cochrane Musculoskeletal Group Satellite Center on Network Meta-analysis. SMG has research support from Novartis and Horizon Therapeutics, and has received consulting fees from Novartis, UCB, and Pfizer. Address correspondence to Jasvinder A. Singh, MBBS, MPH, University of Alabama, Faculty Office Tower 805B, 510 20th Street S, Birmingham, AL 35294. E-mail: Jasvinder.md@gmail.com
Bella Mehta
Birmingham Veterans Affairs (VA) Medical Center, Birmingham, AL; Department of Medicine at the School of Medicine, and Division of Epidemiology at the School of Public Health, University of Alabama at Birmingham, Birmingham, AL 35233; Department of Medicine and Department of Orthopedic Surgery, Hospital for Special Surgery, 535 E 70th Street New York, NY 10021. Grant Support: JAS is supported by the resources and the use of facilities at the VA Medical Center at Birmingham, Alabama, USA. No grant funding was obtained for this study. Financial Conflict: There are no financial conflicts related directly to this study. JAS has received consultant fees from Crealta/Horizon, Medisys, Fidia, UBM LLC, Medscape, WebMD, the National Institutes of Health and the American College of Rheumatology. JAS owns stock options in Amarin pharmaceuticals and Viking therapeutics. JAS is a member of the executive of OMERACT, an organization that develops outcome measures in rheumatology and receives arms-length funding from 36 companies. JAS is a member of the Veterans Affairs Rheumatology Field Advisory Committee. JAS is the editor and the Director of the UAB Cochrane Musculoskeletal Group Satellite Center on Network Meta-analysis. SMG has research support from Novartis and Horizon Therapeutics, and has received consulting fees from Novartis, UCB, and Pfizer. Address correspondence to Jasvinder A. Singh, MBBS, MPH, University of Alabama, Faculty Office Tower 805B, 510 20th Street S, Birmingham, AL 35294. E-mail: Jasvinder.md@gmail.com
Serene Z. Mirza
Birmingham Veterans Affairs (VA) Medical Center, Birmingham, AL; Department of Medicine at the School of Medicine, and Division of Epidemiology at the School of Public Health, University of Alabama at Birmingham, Birmingham, AL 35233; Department of Medicine and Department of Orthopedic Surgery, Hospital for Special Surgery, 535 E 70th Street New York, NY 10021. Grant Support: JAS is supported by the resources and the use of facilities at the VA Medical Center at Birmingham, Alabama, USA. No grant funding was obtained for this study. Financial Conflict: There are no financial conflicts related directly to this study. JAS has received consultant fees from Crealta/Horizon, Medisys, Fidia, UBM LLC, Medscape, WebMD, the National Institutes of Health and the American College of Rheumatology. JAS owns stock options in Amarin pharmaceuticals and Viking therapeutics. JAS is a member of the executive of OMERACT, an organization that develops outcome measures in rheumatology and receives arms-length funding from 36 companies. JAS is a member of the Veterans Affairs Rheumatology Field Advisory Committee. JAS is the editor and the Director of the UAB Cochrane Musculoskeletal Group Satellite Center on Network Meta-analysis. SMG has research support from Novartis and Horizon Therapeutics, and has received consulting fees from Novartis, UCB, and Pfizer. Address correspondence to Jasvinder A. Singh, MBBS, MPH, University of Alabama, Faculty Office Tower 805B, 510 20th Street S, Birmingham, AL 35294. E-mail: Jasvinder.md@gmail.com
Mark P. Figgie
Birmingham Veterans Affairs (VA) Medical Center, Birmingham, AL; Department of Medicine at the School of Medicine, and Division of Epidemiology at the School of Public Health, University of Alabama at Birmingham, Birmingham, AL 35233; Department of Medicine and Department of Orthopedic Surgery, Hospital for Special Surgery, 535 E 70th Street New York, NY 10021. Grant Support: JAS is supported by the resources and the use of facilities at the VA Medical Center at Birmingham, Alabama, USA. No grant funding was obtained for this study. Financial Conflict: There are no financial conflicts related directly to this study. JAS has received consultant fees from Crealta/Horizon, Medisys, Fidia, UBM LLC, Medscape, WebMD, the National Institutes of Health and the American College of Rheumatology. JAS owns stock options in Amarin pharmaceuticals and Viking therapeutics. JAS is a member of the executive of OMERACT, an organization that develops outcome measures in rheumatology and receives arms-length funding from 36 companies. JAS is a member of the Veterans Affairs Rheumatology Field Advisory Committee. JAS is the editor and the Director of the UAB Cochrane Musculoskeletal Group Satellite Center on Network Meta-analysis. SMG has research support from Novartis and Horizon Therapeutics, and has received consulting fees from Novartis, UCB, and Pfizer. Address correspondence to Jasvinder A. Singh, MBBS, MPH, University of Alabama, Faculty Office Tower 805B, 510 20th Street S, Birmingham, AL 35294. E-mail: Jasvinder.md@gmail.com
Peter Sculco
Birmingham Veterans Affairs (VA) Medical Center, Birmingham, AL; Department of Medicine at the School of Medicine, and Division of Epidemiology at the School of Public Health, University of Alabama at Birmingham, Birmingham, AL 35233; Department of Medicine and Department of Orthopedic Surgery, Hospital for Special Surgery, 535 E 70th Street New York, NY 10021. Grant Support: JAS is supported by the resources and the use of facilities at the VA Medical Center at Birmingham, Alabama, USA. No grant funding was obtained for this study. Financial Conflict: There are no financial conflicts related directly to this study. JAS has received consultant fees from Crealta/Horizon, Medisys, Fidia, UBM LLC, Medscape, WebMD, the National Institutes of Health and the American College of Rheumatology. JAS owns stock options in Amarin pharmaceuticals and Viking therapeutics. JAS is a member of the executive of OMERACT, an organization that develops outcome measures in rheumatology and receives arms-length funding from 36 companies. JAS is a member of the Veterans Affairs Rheumatology Field Advisory Committee. JAS is the editor and the Director of the UAB Cochrane Musculoskeletal Group Satellite Center on Network Meta-analysis. SMG has research support from Novartis and Horizon Therapeutics, and has received consulting fees from Novartis, UCB, and Pfizer. Address correspondence to Jasvinder A. Singh, MBBS, MPH, University of Alabama, Faculty Office Tower 805B, 510 20th Street S, Birmingham, AL 35294. E-mail: Jasvinder.md@gmail.com
Michael Parks
Birmingham Veterans Affairs (VA) Medical Center, Birmingham, AL; Department of Medicine at the School of Medicine, and Division of Epidemiology at the School of Public Health, University of Alabama at Birmingham, Birmingham, AL 35233; Department of Medicine and Department of Orthopedic Surgery, Hospital for Special Surgery, 535 E 70th Street New York, NY 10021. Grant Support: JAS is supported by the resources and the use of facilities at the VA Medical Center at Birmingham, Alabama, USA. No grant funding was obtained for this study. Financial Conflict: There are no financial conflicts related directly to this study. JAS has received consultant fees from Crealta/Horizon, Medisys, Fidia, UBM LLC, Medscape, WebMD, the National Institutes of Health and the American College of Rheumatology. JAS owns stock options in Amarin pharmaceuticals and Viking therapeutics. JAS is a member of the executive of OMERACT, an organization that develops outcome measures in rheumatology and receives arms-length funding from 36 companies. JAS is a member of the Veterans Affairs Rheumatology Field Advisory Committee. JAS is the editor and the Director of the UAB Cochrane Musculoskeletal Group Satellite Center on Network Meta-analysis. SMG has research support from Novartis and Horizon Therapeutics, and has received consulting fees from Novartis, UCB, and Pfizer. Address correspondence to Jasvinder A. Singh, MBBS, MPH, University of Alabama, Faculty Office Tower 805B, 510 20th Street S, Birmingham, AL 35294. E-mail: Jasvinder.md@gmail.com
Susan M. Goodman
Birmingham Veterans Affairs (VA) Medical Center, Birmingham, AL; Department of Medicine at the School of Medicine, and Division of Epidemiology at the School of Public Health, University of Alabama at Birmingham, Birmingham, AL 35233; Department of Medicine and Department of Orthopedic Surgery, Hospital for Special Surgery, 535 E 70th Street New York, NY 10021. Grant Support: JAS is supported by the resources and the use of facilities at the VA Medical Center at Birmingham, Alabama, USA. No grant funding was obtained for this study. Financial Conflict: There are no financial conflicts related directly to this study. JAS has received consultant fees from Crealta/Horizon, Medisys, Fidia, UBM LLC, Medscape, WebMD, the National Institutes of Health and the American College of Rheumatology. JAS owns stock options in Amarin pharmaceuticals and Viking therapeutics. JAS is a member of the executive of OMERACT, an organization that develops outcome measures in rheumatology and receives arms-length funding from 36 companies. JAS is a member of the Veterans Affairs Rheumatology Field Advisory Committee. JAS is the editor and the Director of the UAB Cochrane Musculoskeletal Group Satellite Center on Network Meta-analysis. SMG has research support from Novartis and Horizon Therapeutics, and has received consulting fees from Novartis, UCB, and Pfizer. Address correspondence to Jasvinder A. Singh, MBBS, MPH, University of Alabama, Faculty Office Tower 805B, 510 20th Street S, Birmingham, AL 35294. E-mail: Jasvinder.md@gmail.com
In this issue
The Journal of Rheumatology
Vol. 51, Issue 4
1 Apr 2024
Accepted manuscript
When has a knee or hip replacement failed? A patient perspective
Jasvinder A. Singh, Bella Mehta, Serene Z. Mirza, Mark P. Figgie, Peter Sculco, Michael Parks, Susan M. Goodman
The Journal of Rheumatology Dec 2019, jrheum.191024; DOI: 10.3899/jrheum.191024